Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has fomented a climate of fear worldwide due to its rapidly spreading nature, and high mortality rate. The World Health Organization (WHO) declared it as a global pandemic on 11th March, 2020. Many endeavors have been made to find appropriate medications to restrain the SARS CoV-2 infection from spreading but there is no specific antiviral therapy to date. However, a computer-aided drug design approach can be an alternative to identify probable drug candidates within a short time. SARS-CoV-2 main protease is a proven drug target, and it plays a pivotal role in viral replication and transcription. Methods: In this study, we identified a total of 114 essential oil compounds as a feasible anti-SARS-CoV-2 agent from several online reservoirs. These compounds were screened by incorporating ADMET profiling, molecular docking, and 50 ns of molecular dynamics simulation to identify potential drug candidates against the SARS-CoV-2 main protease. The crystallized SARS-CoV-2 main protease structure was collected from the RCSB PDB database (PDB ID 6LU7). Results: According to the results of the ADMET study, none of the compounds have any side effects that could reduce their druglikeness or pharmacokinetic properties. Out of 114 compounds, we selected bisabololoxide B, eremanthin, and leptospermone as our top drug candidates based on their higher binding affinity scores, and strong interaction with the Cys 145-His 41 catalytic dyad. Finally, the molecular dynamics simulation was implemented to evaluate the structural stability of the ligand-receptor complex. MD simulations disclosed that all the hits showed conformational stability compared to the positive control α-ketoamide. Conclusions: Our study showed that the top three hits might work as potential anti-SARS-CoV-2 agents, which can pave the way for discovering new drugs, but for experimental validation, they will require more in vivo trials.

Highlights

  • A new strain of coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a variety of respiratory diseases that emerged in Wuhan, Hubei province, China towards the end of 2019, and since has spread globally.[1,2] SARS-CoV-2 is a positive sense, enveloped RNA virus that belongs to the β genus of the coronaviridae family.[3]

  • ADMET profiling The propensity of a drug to acquire pharmacologically active concentration at targeted therapies can be evaluated by a set of ADME parameters

  • The ADMET properties and drug-likeness of each essential oil compound were determined in this study (See underlying data file, ADME.xlsx).[54]

Read more

Summary

Introduction

A new strain of coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a variety of respiratory diseases that emerged in Wuhan, Hubei province, China towards the end of 2019, and since has spread globally.[1,2] SARS-CoV-2 is a positive sense, enveloped RNA virus that belongs to the β genus of the coronaviridae family.[3] Live animals like bats sold at the local Huanan seafood wholesale market are thought to be a possible point of origin of SARS-CoV-2 as most of the fatalities are inhabited nearby it.[4] Patients with SARS-CoV-2 infection suffer from a fever at the preliminary stage of the disease as a clinical symptom with some other symptoms including headache, dry cough, difficulty breathing, and pneumonia.[5] Progressive respiratory failure due to alveolar damage with the initiation of the disease can even cause the death of the patient.[6] Considering the potential health risks associated with this disease, a therapeutic strategy to reduce the transmission rate is urgently needed, but no specific drugs have yet been discovered.[7] Several medications like ritonavir, lopinavir, oseltamivir, and ganciclovir have been assayed as yet for the inhibition of SARS-CoV-2. Out of 114 compounds, we selected bisabololoxide B, eremanthin, and leptospermone as our top drug

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call